Fidelity Suite

Overview

Fidelity Suite is the perceptual-bandwidth subscription Helix Pharma sells to Elevation- and Transcendence-tier subscribers whose annual Optimize diagnostic has flagged perceptual variance. The product is administered as a slim ear-and-temple wearable with a daily neural-handshake activation, calibrated quarterly to the subscriber's perceptual-bandwidth profile. Helix's clinical literature classifies the variance as resolution sickness; the brand markets the subscription as the regimen that "restores" the bandwidth. The brand is sincere: perception, restored — compliance, continuous.

The product is also, in audit terms, the most documented monetization-of-internal-classification on Helix's books. Resolution sickness was identified by Helix engineers in 2176 as "non-critical perceptual variance within normal operating parameters" and classified as non-critical in three subsequent audits. In 2183, the same engineering organization reclassified the variance as a treatable condition and launched the Fidelity Suite at ¢14,000 per year with a 4.7% cancellation rate, achieving a target metric the Board reviews quarterly. The Suite does not restore stripped perceptual bandwidth; it temporarily reallocates 3-5% cognitive bandwidth to sensory channels, creating a new dependency rung users rarely step down from. Internal materials describe the reallocation as "fidelity discipline." The 4.7% cancellation rate has held within tolerance every year since launch.

Packaging & Appearance

The Fidelity Suite wearable is a surgical-white slim ear-and-temple band with the Helix double-helix etched in deep green into the soft-touch surface and a soft cyan reallocation halo at the neural-handshake antenna near the temple. The halo brightens at activation and dims after the daily reallocation cycle completes. The band is sized to the gloved hand of the consulting Helix clinician at the counter, where the device is paired to the subscriber's perceptual-bandwidth profile. The translucent readout displays the calibrated 3-5% reallocation curve, the metric labeled in clinical proprietary capitalization. The label carries regulatory text in three font sizes and a QR code linking to a 47-page reallocation document available only to credentialed clinicians under NDA. The wearable is engineered to be photographed at the post-reallocation moment when the subscriber is calm at affect baseline.

Ingredients